Changes to Biohit Oyj’s management

MD, Ph.D., FIAC Kari Syrjänen (b. 1948) has been appointed as Chief Medical Director and a member of the management team in Biohit Oyj. Syrjänen has been operating for more than 40 years in various universities and hospitals in Finland and abroad, among others as professor of pathology and chairman of department, dean of the faculty, as well as a visiting professor at several foreign universities and research institutes.

Additional information:
CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealtcare.com

Biohit Oyj in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was established in 1988. Biohit’s mission is “Innovating for Health” and “Cancer Prevention”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to responsibility and it is our duty to innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located China and UK. Since 1999, Biohit’s Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.